Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 1
1992 2
1996 2
1997 1
1999 2
2000 2
2002 3
2003 2
2004 4
2005 3
2006 4
2007 5
2008 8
2009 7
2010 10
2011 10
2012 17
2013 11
2014 16
2015 12
2016 19
2017 21
2018 14
2019 16
2020 17
2021 15
2022 13
2023 15
2024 8
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Results by year

Filters applied: . Clear all
Page 1
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.
Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK. Schlesinger N, et al. Among authors: alten re. Ann Rheum Dis. 2012 Nov;71(11):1839-48. doi: 10.1136/annrheumdis-2011-200908. Epub 2012 May 14. Ann Rheum Dis. 2012. PMID: 22586173 Clinical Trial.
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.
Kristensen LE, Ng KJ, Ngantcha M, Morel J, Lubrano E, Tillett W, Alten R, Chandran V, Martinez Ferrer À, Zhu B, Kennedy D, Holzkämper T, Gullick N, Kronbergs A, Fakhouri W, de la Torre I, McGonagle DG. Kristensen LE, et al. Among authors: alten r. RMD Open. 2024 Sep 20;10(3):e004318. doi: 10.1136/rmdopen-2024-004318. RMD Open. 2024. PMID: 39306343 Free PMC article.
Macrophagic Myofasciitis.
Stenzel W, Heppner FL, Goebel HH, Alten RH. Stenzel W, et al. Among authors: alten rh. Dtsch Arztebl Int. 2009 Apr;106(14):248. doi: 10.3238/arztebl.2009.0248a. Epub 2009 Apr 3. Dtsch Arztebl Int. 2009. PMID: 19547641 Free PMC article. No abstract available.
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. van Vollenhoven RF, et al. N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. N Engl J Med. 2012. PMID: 22873531 Free article. Clinical Trial.
New concepts to reduce glucocorticoid toxicity.
Alten R, Mischkewitz M. Alten R, et al. Joint Bone Spine. 2019 Nov;86(6):715-723. doi: 10.1016/j.jbspin.2018.11.006. Epub 2018 Dec 5. Joint Bone Spine. 2019. PMID: 30528678 Review.
Predicting abatacept retention using machine learning.
Alten R, Behar C, Merckaert P, Afari E, Vannier-Moreau V, Ohayon A, Connolly SE, Najm A, Juge PA, Liu G, Rai A, Elbez Y, Lozenski K. Alten R, et al. Arthritis Res Ther. 2025 Feb 1;27(1):20. doi: 10.1186/s13075-025-03484-0. Arthritis Res Ther. 2025. PMID: 39893489 Free PMC article.
Maximizing the success of biosimilar implementation.
Alten R, Weinbrecht-Mischkewitz M. Alten R, et al. Nat Rev Rheumatol. 2023 Dec;19(12):757-758. doi: 10.1038/s41584-023-01048-7. Nat Rev Rheumatol. 2023. PMID: 37903917 No abstract available.
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F; MUST Investigator Group. Koehm M, et al. Lancet Rheumatol. 2023 Jan;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0. Lancet Rheumatol. 2023. PMID: 38251504 Clinical Trial.
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W, Issa M, Haladyj E, De La Torre I, Grond S, Wollenberg A. Taylor PC, et al. Among authors: alten r. Adv Ther. 2023 Apr;40(4):1867-1883. doi: 10.1007/s12325-023-02445-w. Epub 2023 Feb 20. Adv Ther. 2023. PMID: 36802049 Free PMC article. Clinical Trial.
[Autoimmune reactions to immune checkpoint inhibitors].
Pönisch W, Alten R, Baerwald C. Pönisch W, et al. Among authors: alten r. Z Rheumatol. 2017 Oct;76(Suppl 2):57-62. doi: 10.1007/s00393-017-0368-3. Z Rheumatol. 2017. PMID: 29330759 Review. German.
243 results